Search results for " Metastasis."

showing 10 items of 617 documents

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced…

2019

Abstract Purpose: IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells (Treg). Navoximod is an investigational small-molecule inhibitor of IDO1. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of navoximod in combination with atezolizumab, a PD-L1 inhibitor, in patients with advanced cancer. Patients and Methods: The study consisted of a 3+3 dose-escalation stage (n = 66) and a tumor-specific expansion stage (n = 92). Navoximod was given orally every 12 hours continuously for 21 consecu…

0301 basic medicineAdultCancer ResearchIndoles[SDV]Life Sciences [q-bio][SDV.BC]Life Sciences [q-bio]/Cellular BiologyPharmacologyAntibodies Monoclonal HumanizedArticleB7-H1 Antigen03 medical and health sciences0302 clinical medicinePharmacokineticsAtezolizumabRenal cell carcinomaNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIndoleamine-Pyrrole 23-DioxygenaseNeoplasm MetastasisAgedNeoplasm StagingAged 80 and overBladder cancerbusiness.industryMelanomaImidazolesMiddle Agedmedicine.diseaseMagnetic Resonance Imaging3. Good health030104 developmental biologyTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisPharmacodynamicsPD-L1 inhibitorbusinessTomography X-Ray Computed
researchProduct

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

2019

Background: Changes in the clinical subtype (CS) and intrinsic subtype (IS) between breast cancer (BC) metastases and corresponding primary tumours have been reported. However, their relationship with tumour genomic changes remains poorly characterised. Here, we analysed the association between genomic remodelling and subtype conversion in paired primary and metastatic BC samples. Methods: A total of 57 paired primary and metastatic tumours from GEICAM/2009-03 (ConvertHER, NCT01377363) study participants with centrally assessed CS (n = 57) and IS (n = 46) were analysed. Targeted capture and next-generation sequencing of 202 genes on formalin-fixed paraffin-embedded samples was performed. Th…

0301 basic medicineAdultCancer ResearchSkin NeoplasmsBioinformaticsBone NeoplasmsBreast Neoplasmsmedicine.disease_causeMetastatic tumours03 medical and health sciences0302 clinical medicineBreast cancerBreast cancermedicineBiomarkers TumorHumansProspective StudiesPAM50AgedAged 80 and overMutationIntrinsic subtypebusiness.industryHuman epidermal growth factorBrain NeoplasmsClonal architectureHigh-Throughput Nucleotide SequencingClonal remodellingMiddle Agedmedicine.diseasePrognosisGene Expression Regulation Neoplastic030104 developmental biologyOncology030220 oncology & carcinogenesisLymphatic MetastasisCancer cellMutationCancer researchFemaleNeoplasm Recurrence LocalClinical subtypeHeterogeneitybusinessHormoneFollow-Up Studies
researchProduct

Proinflammatory cytokines as serum biomarker in oral carcinoma-A prospective multi-biomarker approach.

2017

BACKGROUND Inflammation and cell-mediated immunity have a key role in different stages of carcinogenesis. The aim of this prospective study was to assess serum levels of proinflammatory cytokines interleukin-6 (IL-6), interleukin-8 (IL-8), soluble interleukin-2 receptor (sIL-2R), tumor necrosis factor alpha (TNF-α), and MHC class I polypeptide-related sequence B (MICB) in patients with oral premalignant lesion (OPL), oral squamous cell carcinoma (OSCC), and healthy controls in a multi-biomarker approach as a potential diagnostic and prognostic tool for OSCC. MATERIAL AND METHODS A total of 205 patients (81 with OSCC, 75 with OPL, and 49 healthy controls) were included in this prospective st…

0301 basic medicineAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentInflammationGastroenterologyPathology and Forensic MedicineProinflammatory cytokine03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineCarcinomaBiomarkers TumorMedicineHumansProspective StudiesProspective cohort studySurvival rateAgedAged 80 and overbusiness.industryMiddle Agedmedicine.diseasePrognosisstomatognathic diseases030104 developmental biologyCytokineOtorhinolaryngology030220 oncology & carcinogenesisCase-Control StudiesLymphatic MetastasisCarcinoma Squamous CellPeriodonticsBiomarker (medicine)CytokinesTumor necrosis factor alphaFemaleMouth NeoplasmsOral Surgerymedicine.symptombusinessJournal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
researchProduct

Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer

2019

Research question: Does ovarian stimulation for oocyte vitrification affect disease-free survival and overall survival rates in women with early breast cancer? Design: This cohort study included 259 patients with early breast cancer; 148 patients underwent ovarian stimulation, whereas 111 patients did not. Patients were treated between January 2008 and December 2016. To calculate the disease-free survival time and overall survival rate, the time of definitive surgery was defined as the starting point. The follow-up was conducted up to 5 years. Results: Exposed and non-exposed groups were comparable in tumour, node and metastases classification, Nottingham grade, hormonal receptor status, tu…

0301 basic medicineAdultmedicine.medical_specialtyAdolescentDisease-free survivalStimulationBreast NeoplasmsKaplan-Meier EstimateOverall survival rateGastroenterologyDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerBreast cancerOvulation InductionInternal medicinemedicineHumansFertility preservationProspective StudiesStage (cooking)Neoplasm MetastasisFertility preservationRetrospective StudiesCryopreservation030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyFertility PreservationHistologymedicine.diseaseVitrificationConfidence intervalSurvival Rate030104 developmental biologyTreatment OutcomeReproductive MedicineOocytesFemaleOvarian stimulationNeoplasm Recurrence LocalbusinessDevelopmental BiologyCohort studyHormoneFollow-Up Studies
researchProduct

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

2016

// Daniele Fanale 1, * , Valeria Amodeo 1, * , Viviana Bazan 1, * , Lavinia Insalaco 1 , Lorena Incorvaia 1 , Nadia Barraco 1 , Marta Castiglia 1 , Sergio Rizzo 1 , Daniele Santini 2 , Antonio Giordano 3 , Sergio Castorina 4, 5, # , Antonio Russo 1, # 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 University Campus Bio-Medico, Department of Medical Oncology, Rome, Italy 3 Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA 4 Fondazione Mediterranea “G.B. Morgagni”, Catania, Italy 5 Department of Biomedic…

0301 basic medicineAntineoplastic AgentsBreast NeoplasmsBioinformatics03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancermicroRNAmedicineHumansZoledronic acidPI3K/AKT/mTOR pathwaybone metastasisBone Density Conservation AgentsDiphosphonatesMicroarray analysibusiness.industryGene Expression ProfilingImidazolesBone metastasisMicroRNA Expression Profilemedicine.diseaseActin cytoskeletonMolecular medicineBone metastasis; Breast cancer; Microarray analysis; miRNA expression profile; Zoledronic acid; Oncology030104 developmental biologyZoledronic acidOncologyBone metastasi030220 oncology & carcinogenesisMCF-7 CellsCancer researchmiRNA expression profilemicroarray analysisTranscriptomebusinessResearch Papermedicine.drug
researchProduct

A headlight on liquid biopsies: a challenging tool for breast cancer management

2016

Breast cancer is the most frequent carcinoma and second most common cause of cancer-related mortality in postmenopausal women. The acquisition of somatic mutations represents the main mechanism through which cancer cells overcome physiological cellular signaling pathways (e.g., PI3K/Akt/mTOR, PTEN, TP53). To date, diagnosis and metastasis monitoring is mainly carried out through tissue biopsy and/or re-biopsy, a very invasive procedure limited only to certain locations and not always feasible in clinical practice. In order to improve disease monitoring over time and to avoid painful procedure such as tissue biopsy, liquid biopsy may represent a new precious tool. Indeed, it represents a bas…

0301 basic medicineCA15-3OncologyCancer Researchmedicine.medical_specialtyPathologyBiopsyBreast NeoplasmsMetastasis03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerCirculating tumor cellInternal medicineBiopsyBiomarkers TumormedicineCarcinomaHumansPTENNeoplasm MetastasisLiquid biopsyBreast cancer; Circulating tumor cells; Circulating tumor DNA; CTCs; ctDNA; Liquid biopsy; Cancer ResearchCirculating tumor DNALiquid biopsybiologymedicine.diagnostic_testbusiness.industryCirculating tumor cellctDNADNA NeoplasmGeneral MedicineNeoplastic Cells Circulatingmedicine.diseaseCTC030104 developmental biology030220 oncology & carcinogenesisbiology.proteinFemalebusinessTumor Biology
researchProduct

Critical Roles of EGFR family members in breast cancer and breast cancer stem cells: Targets for therapy

2016

The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980's. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses o…

0301 basic medicineCA15-3OncologyEGFR HER2 mIRs Cancer Stem Cells Drug Resistance Metastasismedicine.medical_specialtyEGFRDrug ResistancemIRCancer Stem CellBreast NeoplasmsNOMetastasisMetastasis03 medical and health sciences0302 clinical medicineBreast cancerCancer stem cellInternal medicineCancer Stem CellsHER2Drug DiscoverymicroRNAmedicineCancer Stem Cells; Drug Resistance; EGFR; HER2; Metastasis; mIRs; Pharmacology; Drug Discovery3003 Pharmaceutical ScienceAnimalsHumansEpidermal growth factor receptorPharmacologyCancer Stem Cells; Drug Resistance; EGFR; HER2; Metastasis; mIRsmIRsbiologybusiness.industryEGFR HER2 mIRs Cancer Stem Cells Drug Resistance Metastasis.Drug Discovery3003 Pharmaceutical ScienceCancermedicine.disease3. Good healthErbB Receptors030104 developmental biology030220 oncology & carcinogenesisbiology.proteinNeoplastic Stem CellsFemaleStem cellbusinessSignal Transduction
researchProduct

Relevance of 3d culture systems to study osteosarcoma environment

2018

Abstract Osteosarcoma (OS) is the most common primary malignant tumor of bone, which preferentially develops lung metastasis. Although standard chemotherapy has significantly improved long-term survival over the past few decades, the outcome for patients with metastatic or recurrent OS remains dramatically poor. Novel therapies are therefore required to slow progression and eradicate the disease. Furthermore, to better understand the cellular and molecular mechanisms responsible for OS onset and progression, the development of novel predictive culture systems resembling the native three-dimensional (3D) tumor microenvironment are mandatory. ‘Tumor engineering’ approaches radically changed t…

0301 basic medicineCancer Research3D cell culture system; Osteosarcoma; Scaffolds; SpheroidsLung metastasisCell Culture TechniquesBone NeoplasmsReviewDiseaselcsh:RC254-282Scaffold03 medical and health sciences3D cell culture0302 clinical medicineSettore BIO/13 - Biologia ApplicataSlow progressionSpheroids CellularTumor MicroenvironmentmedicineAnimalsHumans3D cell culture systemScaffoldsOsteosarcomaTumor microenvironmentTissue Scaffoldsbusiness.industrylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease3. Good healthClinical Practice030104 developmental biologyOncologyCell culture030220 oncology & carcinogenesisCancer researchOsteosarcomaSpheroidsbusinessJournal of Experimental & Clinical Cancer Research
researchProduct

Prevention of carcinogenesis and metastasis by Artemisinin-type drugs.

2018

Artemisia annua (sweet wormwood, qinhao) is an ancient Chinese herbal remedy for pyrexia. Nowadays, artemisinin (qinghaosu) and its derivatives belong to the standard therapies against malaria worldwide, and its discovery has led to the Nobel Prize in Physiology and Medicine to Youyou Tu in 2015. While most attention has been paid to the treatment of malaria, there is increasing evidence that Artemisinin-type drugs bear a considerable potential to treat and prevent cancer. Rather than reporting on therapy of cancer, this review gives a comprehensive and timely overview on the chemopreventive effects of artemisinin and its derivatives against carcinogenesis and metastasis formation, followin…

0301 basic medicineCancer ResearchCarcinogenesisArtemisia annuaCancer metastasisArtemisia annuaBioinformaticsmedicine.disease_causeMetastasis03 medical and health sciencesAntimalarials0302 clinical medicineNeoplasmsparasitic diseasesmedicineHumansArtemisininNeoplasm MetastasisToxicity profileClinical Trials as TopicbiologyMolecular Structurebusiness.industryCancermedicine.diseasebiology.organism_classificationArtemisinins030104 developmental biologyOncology030220 oncology & carcinogenesisCarcinogenesisbusinessMalariamedicine.drugPhytotherapyCancer letters
researchProduct

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver

2021

Metastasis is facilitated by the formation of a "premetastatic niche," which is fostered by primary tumor-derived factors. Colorectal cancer (CRC) metastasizes mainly to the liver. We show that the premetastatic niche in the liver is induced by bacteria dissemination from primary CRC. We report that tumor-resident bacteria Escherichia coli disrupt the gut vascular barrier (GVB), an anatomical structure controlling bacterial dissemination along the gut-liver axis, depending on the virulence regulator VirF. Upon GVB impairment, bacteria disseminate to the liver, boost the formation of a premetastatic niche, and favor the recruitment of metastatic cells. In training and validation cohorts of C…

0301 basic medicineCancer ResearchColorectal cancerRegulatorVirulencemedicine.disease_causeMetastasis03 medical and health sciences0302 clinical medicinemedicineHumansNeoplasm MetastasisEscherichia coliBacteriabiologybusiness.industryLiver NeoplasmsDistant recurrencebiology.organism_classificationmedicine.disease030104 developmental biologyLiverOncology030220 oncology & carcinogenesisColonic NeoplasmsCancer researchIntestinal bacteriaNeoplasm Recurrence LocalColorectal NeoplasmsbusinessBacteriaCancer Cell
researchProduct